Clinical trial

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT05078047

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-03-08

PhasePHASE3

Study timeline

Study start (actual)2022-03-08Date precision: day

Registry last updated2026-07-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer Metastaticunresolved

Renal Cell Carcinomaunresolved

Head and Neck Cancerunresolved

Triple Negative Breast Cancerunresolved

Merkel Cell Carcinomaunresolved

Hepatocellular Carcinomaunresolved

Melanomaunresolved

Urothelial Carcinomaunresolved

Colorectal Carcinoma With Microsatellite Instabilityunresolved

Esophageal Squamous Cell Carcinomaunresolved

Endometrial Carcinomaunresolved

Cervical Cancerunresolved

Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinomaunresolved

Basal Cell Carcinomaunresolved

Squamous Skin Carcinomaunresolved

Interventions

Reduced dose intensity of IODRUG

Sponsors & collaborators

UNICANCERlead sponsor

Mapped research locations

ParisFrance3 LyonFrance2 CréteilFrance2 ToulouseFrance1 StrasbourgFrance1 LilleFrance1 BordeauxFrance1 RennesFrance1 NiceFrance1 DijonFrance1 Clermont-FerrandFrance1 CaenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05078047 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.